WELL Health Hits Its Number and Lowers Its Other Number
The headline out of WELL Health's fiscal Q3 2026 call is unambiguous and, for once, arithmetic rather than rhetorical: the Canadian clinics business crossed a $100 million annualized adjusted EBITDA run rate, a target management had set for the end of 2026, and did it one quarter early. Canadian clinic revenue rose 49% to $164.9 million, segment adjusted EBITDA rose 82% to $25.7 million, and segment margin expanded roughly 280 basis points to 15.6%.
Now the other number. Same call, same paragraph of the script: “We now expect revenue of approximately $1.58 billion, which was on the lower end of our guidance range.” — Hamed Shahbazi, Chief Executive Officer (CEO) · 2026-11-09 Adjusted EBITDA guidance was held at $185–195 million. A company that trims the top line while holding the profit line is telling you something specific about where its margin is coming from — and WELL is telling it loudly.
The Engine Room, Redefined
Buried in the operational section is a change that deserves more attention than it got: WELL redefined what a "clinic" is. Under the new definition — a distinct health care service defined by brand, business or P&L, care team or EMR — the company operates 302 clinics across 179 physical facilities, with history restated to match. That produced a cluster of fresh vocabulary on the quarter: clinic count, physical facility, and a restated base going back to 128 clinics at the start of 2022. It is a defensible definitional cleanup. It is also the kind of change that makes a growth series look smoother than a like-for-like comparison would.
The underlying operating metrics, though, back the milestone rather than decorate it. Patient visits in Canada hit 1.29 million, up 20% year-over-year — of which 6% was organic, split 1.9% same-clinic and 4.1% from absorptions. Visits per billable provider reached approximately 534, up 3% year-over-year and 18% from roughly 441 two years ago. That productivity curve is the physical evidence behind the clinic transformation program and the tech enablement story management has been telling for several quarters now.
One wrinkle worth flagging: same-clinic sales growth of 12% ran far ahead of 6% organic visit growth, and analyst Michael Freeman pressed on it. Hamed Shahbazi conceded a retroactive reimbursement contribution: “we did have some retro reimbursement that contributed in the quarter... I think we were essentially somewhere in kind of like just shy of 10% same clinic sales growth overall in clinics.” — Hamed Shahbazi, Chief Executive Officer (CEO) · 2026-11-09 Still elevated. But 10%, not 12%, is the cleaner read on the underlying engine.
The Pivot Nobody Named as a Pivot
The single most telling keyword shift this quarter is the arrival of public sector at the very top of the company's theme list — a theme that had no meaningful presence in WELL's prior vocabulary. It arrives attached to OneWELL, the integrated offering spanning WELL clinics, WELLSTAR and HEALWELL, and to a pipeline management describes as: “actively engaged at the federal and with a number of provincial health authorities pursuing opportunities that represent well over $100 million in contract value.” — Hamed Shahbazi, Chief Executive Officer (CEO) · 2026-11-09 To their credit, the company drew the line explicitly — "pipeline opportunities under active pursuit, not contracted revenue."
Read against the prior calls, this is a strategic reframing rather than a new business. In August, the public-sector story was WELLSTAR's e-referral land grab: “all of the regions ended up going with OceanMD. That was a very significant event for OceanMD.” — Hamed Shahbazi, Chairman and Chief Executive Officer · 2026-08-06 Today it is a single accountable partner selling the whole stack — clinics, software and clinical AI — into provincial systems. The appeal to sovereignty (patient data staying in Canada) and interoperability (Bill S-5) is new packaging on an old capability. Cynically, it is also the argument a company needs when it wants to be valued as infrastructure rather than as a roll-up.
Our long-term goal overall with clinics and research altogether is to exceed 20% operating margins for the entire network. And that would include some of your lower-margin kind of more plain vanilla medical clinics as well.
That is a material escalation. In May, the margin language was “our goal is to be well into the double digits over time.” — Hamed Shahbazi, Chairman and Chief Executive Officer · 2026-05-10 Two quarters later, the ambition is north of 20% for the whole network, with site management organization work — pharma-activating the clinical base — as the bridge. On the call it was framed as "a very small business today" that can contribute hundreds of basis points over years. That is a long-dated promise against a segment currently running 15.6%.
What Is Being Quietly Left Behind
Circle Medical and the deferral saga have finally exited the story. The Deferral impact keyword still ranks highly, but its role has inverted — it now exists only to explain the prior-year comparison, not the current quarter. Reported and normalized results are identical. That is genuinely a simplification.
Less clean is the $135.5 million net loss, driven by $67.5 million of impairments — $39.8 million of it against HEALWELL goodwill. Shahbazi's framing is that this is an accounting artifact of the $1.47-per-share revaluation required at the 2025 control acquisition: “our total cash outlay to build our equity position in HEALWELL was approximately $13.9 million... Today, we own approximately 97 million HEALWELL shares, which at current prices are worth roughly $64.2 million.” — Hamed Shahbazi, Chief Executive Officer (CEO) · 2026-11-09 Fair on the cash math. But it also means a quarter in which reported earnings and economic reality diverged by more than $160 million, and the market has to take management's word on which one to believe.
The U.S. care-delivery assets — CRH, Wisp, Circle Medical — are now explicitly an exit. Two of three processes have "progressed to a more advanced stage with focused counterparties." Wisp's EBITDA nearly tripled to $3.2 million; Circle Medical's normalized EBITDA fell to $2.2 million from $4.8 million on compliance and marketing spend. The message is that these businesses are being groomed for sale, not grown. Canadian clinics are, in the company's own words, the primary destination for incremental capital.
The Cash Doesn't Follow
The awkward fact under all of it: normalized adjusted EBITDA grew 20%, yet operating adjusted free cash flow attributable to shareholders fell to $13.3 million from $15.1 million. New CFO Evelyn Sutherland, on her first call, named it directly: “improving cash conversion remains a very important priority.” — Evelyn Sutherland, Chief Financial Officer (CFO) · 2026-11-09 Three culprits — clinic capital upgrades, higher cash tax payments from acquisitions, and higher interest on the upsized credit line used for ECC, OID and UnionMD.
That last one is the tension inside the capital structure story. The notes offering — $150 million of 6.875% notes due 2031, oversubscribed — plus the WELLSTAR listing converting roughly $155 million of preferred shares into equity and the Competition Bureau's action letter on HEALWELL, all genuinely simplify the balance sheet. But simplification has a coupon. And the federal budget tax-loss transfer proposals management flagged enthusiastically are, by Sutherland's own admission, too early to quantify.
The verdict: WELL has built a real, profitable Canadian clinic engine and is now trying to re-rate itself as a sovereign health-infrastructure platform. The $100 million milestone is earned. The $100 million-plus of public sector "pipeline" is not yet. And the revenue guide moved down while the story moved up — which is precisely the gap an investor should be watching.